

Amendments to the Claims

Please amend Claim 39. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 100 μ M.
2. (Previously presented) The monoclonal antibody of Claim 1 selected from the group consisting of: 1-10 (A.T.C.C. Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813), and an antigen binding fragment thereof.
3. (Original) The monoclonal antibody of Claim 1 which has a binding affinity constant for ouabain of at least about 2×10^{-8} M.
4. (Original) The monoclonal antibody of Claim 1 which has a binding affinity constant for ouabain of at least about $3 \pm 1 \times 10^{-7}$ M.
5. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as a monoclonal antibody selected from the group consisting of: 1-10 (Accession Number PTA-814), 7-1 (A.T.C.C. Accession Number PTA-813), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 100 μ M.
6. (Previously presented) A hybridoma cell line which produces a monoclonal antibody selected from the group consisting of: 1-10 (A.T.C.C. Accession Number PTA-814), 7-1

(A.T.C.C. Accession Number PTA-813), a monoclonal antibody having the same binding specificity as 1-10 (A.T.C.C. Accession Number PTA-814), a monoclonal antibody having the same binding specificity as 7-1 (A.T.C.C. Accession Number PTA-813), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 100 μ M.

7.-37. Canceled.

38. (Previously presented) A pharmaceutical composition comprising a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 100 μ M, and a pharmaceutical acceptable carrier.

39. (Currently amended) A monoclonal antibody or antigen binding fragment thereof produced by a method of making a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain ~~and which does not crossreact with~~ and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin, as high as 100 μ M comprising the steps of:

- a) immunizing a mammal with ouabain bound to an antibody which has binding specificity for a glycoside;
- b) fusing splenocytes of the mammal with immortalized cells to produce hybridomas;
- c) selecting from the hybridomas a hybridoma which produces a monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain and which does not crossreact with digoxin,

wherein the antibody or antigen binding fragment thereof has binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of

the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin, as high as 100 μ M.

40. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 25 μ M.
41. (Previously presented) The monoclonal antibody of Claim 40 wherein the antibody is 5A12 (A.T.C.C. Accession Number PTA-812) or an antigen binding fragment thereof.
42. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as monoclonal antibody 5A12 (A.T.C.C. Accession Number PTA-812) and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 25 μ M.
43. (Previously presented) A hybridoma cell line which produces a monoclonal antibody selected from the group consisting of: 5A12 (A.T.C.C. Accession Number PTA-812), a monoclonal antibody having the same binding specificity as 5A12 (A.T.C.C. Accession Number PTA-812), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 25 μ M.
44. (Previously presented) A pharmaceutical composition comprising a monoclonal antibody or antigen binding and an antigen binding fragment thereof fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 25 μ M, and a pharmaceutical acceptable carrier.

45. (Previously presented) A monoclonal antibody comprising 1-10 (A.T.C.C. Accession Number PTA-814).
46. (Previously presented) A monoclonal antibody comprising 7-1 (A.T.C.C. Accession Number PTA-813).
47. (Previously presented) A monoclonal antibody comprising 8E4 (A.T.C.C. Accession number PTA-815).
48. (Previously presented) A monoclonal antibody comprising 5A12 (A.T.C.C. Accession Number PTA-812).
49. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 1-10 (A.T.T.C. Accession Number PTA-814), wherein the monoclonal antibody or antigen binding fragment thereof has binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex.
50. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 7-1 (A.T.C.C. Accession Number PTA-813), wherein the monoclonal antibody or antigen binding fragment thereof has binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex.
51. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as 8E4 (A.T.C.C. Accession Number PTA-815), wherein the monoclonal antibody or antigen binding fragment thereof has binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex.
52. (Previously presented) A hybridoma cell line which produces monoclonal antibody 1-10 (A.T.C.C. Accession Number PTA-814) or an antigen binding fragment thereof.

53. (Previously presented) A hybridoma cell line which produces monoclonal antibody 7-1 (A.T.C.C. Accession Number PTA-813) or an antigen binding fragment thereof.
54. (Previously presented) A hybridoma cell line which produces monoclonal antibody 8E4 (A.T.C.C. Accession Number PTA-815) or an antigen binding fragment thereof.
55. (Previously presented) A hybridoma cell line which produces monoclonal antibody 5A12 (A.T.C.C. Accession Number PTA-812) or an antigen binding fragment thereof.
56. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 50 μ M.
57. (Previously presented) The monoclonal antibody of Claim 56 wherein the antibody is 8E4 (A.T.C.C. Accession Number PTA-815) or an antigen binding fragment thereof.
58. (Previously presented) A monoclonal antibody or antigen binding fragment thereof having the same binding specificity as monoclonal antibody 8E4 (A.T.C.C. Accession Number PTA-815) and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 50 μ M.
59. (Previously presented) A hybridoma cell line which produces a monoclonal antibody selected from the group consisting of: 8E4 (A.T.C.C. Accession Number PTA-815), a monoclonal antibody having the same binding specificity as 8E4 (A.T.C.C. Accession Number PTA-815), and an antigen binding fragment thereof, wherein the antibody binds ouabain and binding of the antibody to ouabain is not inhibited by a concentration of digoxin as high as 50 μ M.

60. (Previously presented) A pharmaceutical composition comprising a monoclonal antibody or antigen binding and an antigen binding fragment thereof having binding specificity for ouabain and for the ouabain component of a ouabain-carrier complex, wherein binding of the antibody or antigen binding fragment to ouabain is not inhibited by a concentration of digoxin as high as 50 μ M, and a pharmaceutical acceptable carrier.